MMV048

 

Product vision
  • Part of a single-exposure radical cure

  • Potential for prophylaxis

MoA
  • PfPI4K inhibitor

Key features
  • 80mg dose predicted to give coverage above Minimal Parasiticidal Concentration for ≥8 days

  • Good prophylactic activity against P. cynomolgi, in vivo after single dose 

  • Long half-life in human

  • Potential for transmission-blocking activity in a Standard Membrane Feeding Assay

Challenges
  • Preclinical safety limiting further dose escalation in patients

Status
  • Phase IIa in Ethiopia ongoing
Next milestone
  • Initiate recruitment of P. falciparum patients into Phase IIa in Ethiopia
 
Previously
  • Name MMV390048: Discovery and Phase I partnership with H3D, University of Cape Town
MMV Project Director
  • Dr Cristina Donini